Contents

Preface to the second edition *xi*

1. General anesthetics **1**

1.1 Noninhalation components for general anesthesia 2
1.2 Inhalation anesthetics 5
1.3 Synthesis of some general anesthetics 6
1.4 New sedative/anesthetic agent 7
References 9

2. Local anesthetics **11**

2.1 Aminoester anesthetics 13
2.2 Aminoamide anesthetics 14
2.3 Synthesis of some local anesthetics 15
References 17

3. Analgesics **21**

3.1 Nonsteroidal antiinflammatory drugs 22
3.2 Opioid analgesics 33
3.3 Adjunctive agents in the management of pain, or "nonanalgesic" pain killers 47
3.4 Some new attractive scaffolds, unrelated to known opioid analgesics structures 75
References 82

4. Soporific agents (hypnotics and sedative drugs) **95**

4.1 Barbiturates 95
4.2 Histamine H1 receptor antagonists 96
4.3 Benzodiazepines 97
4.4 Z-drugs 98
4.5 New GABA receptor agonists 102
4.6 Melatonergic (MT1/MT2) agonists 103
4.7 5-HT antagonists and antagonists/inverse agonists 103
4.8 NK1-receptor antagonists 105
4.9 Orexin receptor (OX1/OX2) antagonists 106
4.10 Sodium oxybate 107
References 108

5. Anxiolytics (tranquilizers) 111

5.1 Benzodiazepines 112
5.2 Anxiolytic drugs acting on serotonin receptors 114
5.3 Anxiolytic drugs acting on adrenoreceptors 119
5.4 Anxiolytic drugs acting on glutamate receptors 120
5.5 Anxiolytic compounds acting on other receptors 121
5.6 Search for new pharmacologic agents for treatment of anxiety disorders 125
References 128

6. Antipsychotics 133

6.1 First generation antipsychotics 134
6.2 Second generation antipsychotics 138
6.3 Third generation antipsychotics 153
6.4 Search of new pharmacologic agents as antipsychotics 156
References 164

7. Antidepressants 173

7.1 Tricyclic antidepressants 174
7.2 Monoamine oxidase inhibitors 176
7.3 Selective serotonin reuptake inhibitors 177
7.4 Selective norepinephrine (noradrenaline) reuptake inhibitors 189
7.5 Dual uptake inhibitors (SSRI/SNRI) 191
7.6 Dual uptake inhibitors (SNRI/SDARI) 198
7.7 Triple uptake inhibitors (SSRI/SNRI/SDARI) 198
7.8 New-generation multimodal antidepressants 199
References 205

8. Central nervous system stimulants 217

References 229

9. Antiepileptic drugs 233

9.1 Levetiracetam - Keppra 242
References 253

10. Antiparkinsonian drugs 267

10.1 Levodopa, carbidopa, levodopa/carbidopa 268
10.2 Dopamine agonists 272

10.3 Anticholinergics 273
10.4 MAO inhibitors 274
10.5 Catechol-O-methyltransferase inhibitors 274
10.6 Amantadine 275
10.7 New drugs in development for Parkinson's disease 276
10.8 Novel disease-modifying therapeutics targeting α-synuclein pathology 283
10.9 Phytotherapy of Parkinson's disease 288
References 289

11. Adrenergic (sympathomimetic) drugs 293

11.1 α1 receptor activating drugs 295
11.2 α2 receptor activating drugs 297
11.3 β1 Receptor activating drugs 300
11.4 β2 Receptor activating drugs 302
11.5 β3 Receptor activating drugs 307
11.6 Multiple adrenoreceptor activation 309
References 310

12. Adrenoblockers 313

12.1 α-Adrenoblockers 313
12.2 β-Adrenoblockers 319
References 326

13. Cholinomimetics 331

13.1 Direct-acting cholinomimetics 332
13.2 Cholinesterase inhibitors (indirect-acting cholinomimetics) 337
References 344

14. Anticholinergic drugs 349

14.1 Antinicotinic agents (neuromuscular blocking drugs) 349
14.2 Ganglionic blockers 352
14.3 Antimuscarinic agents 352
14.4 Newer neuromuscular blocking agents 364
References 370

15. Centrally acting skeletal muscle relaxants 375

References 384

16. Antihistamine drugs **387**

16.1 H1 antihistamines 388
16.2 H2 antihistamines 399
16.3 H3 antihistamines 400
16.4 H4 antihistamines 403
References 410

17. Cardiotonic inotropic drugs **417**

17.1 Class I Cardiotonic inotropic agents (Drugs that increase the cyclic adenosine monophosphate (cAMP) level) 418
17.2 Class II Cardiotonic inotropic (drugs that regulate ion channels or pumps in the myocardial cell membrane) 420
17.3 Class III Cardiotonic inotropic agents (drugs that modulate intracellular calcium regulation) 422
17.4 Class IV Drugs that modulate intracellular calcium regulation agents (drugs that augment contractility through various mechanisms) 422
17.5 Novel potential cardiotonic inotropic drugs 423
References 429

18. Antiarrhythmic drugs **433**

18.1 Class I Antiarrhythmic drugs 434
18.2 Class II Antiarrhythmic drugs 435
18.3 Class III Antiarrhythmic drugs 436
18.4 Class IV Antiarrhythmic drugs 438
18.5 Class V Antiarrhythmic drugs 438
18.6 Investigational antiarrhythmic agents 440
References 445

19. Antianginal drugs **449**

19.1 Nitrates 449
19.2 Calcium-channel blockers 450
19.3 β-Adrenergic blockers 451
19.4 Novel antianginal drugs 451
References 458

20. Hypolipidemic and antihyperlipidemic drugs **461**

20.1 Statins 462
20.2 Fibrates 470
20.3 Bile acid sequestrants 472

20.4 Iinhibition of absorption of cholesterol from the intestines 475
20.5 Niacin 479
20.6 Omega-3 fatty acids (fish oils) 481
20.7 New agents for the pharmacotherapy of dyslipidemia 482
References 490

21. Diuretics 501

21.1 Carbonic anhydrase inhibitors 503
21.2 Loop diuretics (high ceiling diuretics) 504
21.3 Diuretics acting at distal convoluted tubule (thiazides and thiazide-like diuretics) 505
21.4 Diuretics acting at collecting duct system 508
21.5 Osmotic diuretics 510
21.6 Novel diuretic targets 512
References 526

22. Antihypertensive drugs 533

22.1 Diuretics 535
22.2 Beta-blockers 535
22.3 Calcium-channel blockers 537
22.4 Renin–angiotensin system blockers 538
22.5 Miscellaneous 553
22.6 Novel antihypertensive drugs 556
References 567

Index 577